文献速递胸部肿瘤

电子鼻系统检测肺癌及EGFR突变

Detection of Lung Cancer and EGFR Mutation by Electronic Nose System.
PubMed 文献 · J Thorac Oncol · 2017-07-12

本研究纳入119例疑似肺部病变患者,其中良性结节30例、肺癌89例(早期16例、晚期73例)。采用纳米材料传感器阵列分析呼气样本,模式识别方法可区分EGFR突变型与野生型肺癌(准确率83%),并可区分早期肺癌与良性结节(准确率87%)。

要点

  • 呼气分析可区分EGFR突变型肺癌(n=19)与野生型EGFR(n=34),准确率83%、灵敏度79%、特异度85%。
  • 早期肺癌与良性结节的区分准确率为87%,阳性预测值87.7%、阴性预测值87.5%。
  • 重度吸烟者肺癌与从不吸烟或远期轻度吸烟者肺癌的区分准确率为76%。

核心结论

  • 呼气分析可将携带EGFR突变的肺癌患者与野生型EGFR患者区分开,并可将早期肺癌患者与良性肺结节患者区分开。
  • 若组织取样无法提供足够材料进行确定性突变分析,EGFR突变的阳性呼气印迹或可用于治疗决策。

研究设计与样本

  • 研究纳入因疑似肺部病变接受评估的患者,采集呼气样本。
  • 患者分为良性结节组、肺癌组(伴或不伴EGFR突变),并按吸烟状态分类。
  • 采用纳米材料传感器阵列识别呼气印迹,并使用模式识别方法分析。

主要发现

  • 共119例患者参与,其中良性结节30例、肺癌89例(早期16例、晚期73例)。
  • EGFR突变肺癌患者(n=19)与野生型EGFR患者(n=34)的区分准确率为83%,灵敏度79%,特异度85%。
  • 早期肺癌与良性结节的区分准确率为87%,阳性预测值87.7%、阴性预测值87.5%。
  • 重度吸烟者肺癌与从不吸烟或远期轻度吸烟者肺癌的区分准确率为76%。

临床怎么用

  • 若组织取样无法提供足够材料进行确定性突变分析,EGFR突变的阳性呼气印迹或可用于治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Early detection of lung cancer (LC) has been well established as a significant key point in patient survival and prognosis. New highly sensitive nanoarray sensors for exhaled volatile organic compounds that have been developed and coupled with powerful statistical programs may be used when diseases such as LC are suspected. Detection of genetic aberration mutation by nanoarray sensors is the next target. METHODS: Breath samples were taken from patients who were evaluated for suspicious pulmonary lesions. Patients were classified as those with benign nodules, as patients with LC with or without the EGFR mutation, and according to their smoking status. Breath prints were recognized by nanomaterial-based sensor array, and pattern recognition methods were used. RESULTS: A total of 119 patients participated in this study, 30 patients with benign nodules and 89 patients with LC (16 with early disease and 73 with advanced disease). Patients with LC who harbored the EGFR mutation (n = 19) could be discriminated from those with wild-type EGFR (n = 34) with an accuracy of 83%, sensitivity of 79%, and specificity of 85%. Discrimination of early LC from benign nodules had 87% accuracy and positive and negative predictive values of 87.7 and 87.5% respectively. Moderate discrimination (accuracy of 76%) was found between LC of heavy smokers and that of never-smokers or distant past light smokers. CONCLUSIONS: Breath analysis could discriminate patients with LC who harbor the EGFR mutation from those with wild-type EGFR and those with benign pulmonary nodules from those patients with early LC. A positive breath print for the EGFR mutation may be used in treatment decisions if tissue sampling does not provide adequate material for definitive mutation analysis.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Shlomi D, Abud M, Liran O, et al. Detection of Lung Cancer and EGFR Mutation by Electronic Nose System. J Thorac Oncol. 2017. PMID: 28709937. doi:10.1016/j.jtho.2017.06.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。